Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.
This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Sex | All |
| Sponsor | Tata Memorial Hospital Government |
| Drugs / interventions | chemotherapy, radiation, immunotherapy |
| Locations | 1 site (Mumbai, Maharashtra) |
| Trial ID | NCT07400809 on ClinicalTrials.gov |
What this trial studies
This is a multicentre, retrospective registry collecting real‑world data on patients with induced oligo‑metastatic or oligo‑recurrent cervical cancer identified using an adapted ESTRO‑ASTRO definition. The project will describe treatment patterns, including high‑dose radiotherapy, stereotactic ablative radiotherapy, re‑irradiation, surgery or ablation, given alone or with systemic chemotherapy, immunotherapy, or targeted agents. Primary outcome is overall survival, with secondary endpoints including in‑field and overall progression‑free survival, treatment‑related toxicity, and development of prognostic risk groups. The registry will also support development of a nomogram and a framework to inform future prospective trials.
Who should consider this trial
Good fit: Ideal candidates are people with cervical cancer who have oligo‑metastatic or oligo‑recurrent disease (including those previously treated, those who responded to systemic chemotherapy, or those treated with local therapies such as radiation, surgery, or ablation).
Not a fit: Patients with persistent widespread poly‑metastatic disease without good systemic response, non‑cervical gynecologic cancers, those enrolled on other investigational relapsed‑disease drug trials, or individuals without clinical follow‑up are unlikely to benefit from inclusion in this registry.
Why it matters
Potential benefit: If successful, the registry could identify which patients gain a survival or quality‑of‑life benefit from adding local treatments to systemic therapy, enabling more personalized care.
How similar studies have performed: Prior trials like SABR‑COMET and some institutional series have suggested a potential benefit from local ablative therapies in selected oligometastatic patients, but evidence specific to cervical cancer remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Cervical cancer with (induced) oligo-metastatic and/or oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials/studies. 2. Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site. 3. Patients treated with radical doses at the time of first diagnosis of oligo-metastasis/oligo-recurrence and present with further oligo-progression. 4. Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted. Exclusion Criteria: 1. Gynaecological cancer other than cervical cancer. 2. Persistent Poly-metastatic disease post systemic treatment 3. Receiving investigational new drugs at the time of relapse as part of other ongoing trials. 4. No clinical follow up after treatment
Where this trial is running
Mumbai, Maharashtra
- Tata Memorial Hospital — Mumbai, Maharashtra, India (Recruiting)
Study contacts
- Principal investigator: Dr. Supriya Chopra, MD — ACTREC, Tata Memorial Centre, Navi Mumbai India
- Study coordinator: Dr. Supriya Chopra, MD
- Email: supriyasastri@gmail.com
- Phone: 9930958309
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.